Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial

Rui Fang(German Cancer Research Center), Jinwen Ge(Hunan University of Traditional Chinese Medicine), Qiling Jiang(Shaoyang University), Shaowu Cheng(Hunan University of Traditional Chinese Medicine), Yue Zhou(Hunan University of Traditional Chinese Medicine), Ruining She(Hunan University of Traditional Chinese Medicine), Xiwen Peng(Hunan University of Traditional Chinese Medicine), Yunhua Luo(University of Manitoba), Yao Xie(Hunan Academy of Traditional Chinese Medicine), Zhigang Mei(Hunan University of Traditional Chinese Medicine), Litao Liu(Xi'an University of Science and Technology), Kun Zhang(Kunming University of Science and Technology), Chang Liu(Tianjin University), Wei Wang(First Affiliated Hospital of Hunan University of Traditional Chinese Medicine), Shanshan Wang(Chinese Academy of Sciences), Linyong Xu(Central South University), Hua Hu(First Affiliated Hospital of Hunan University of Traditional Chinese Medicine), Shangzhen Yu(Jinan University), Yifang Lu(Shaoyang University), Zhuyuan Fang(Nanjing University of Chinese Medicine), Xiangyuan Wang(Hunan University of Traditional Chinese Medicine), Tong Jiao(Harvard University), Hongyuan Lin(Hunan University of Traditional Chinese Medicine), Hongcai Shang(Beijing University of Chinese Medicine), Dahua Wu(Hunan Academy of Traditional Chinese Medicine), Le Xie(Nankai University)
Frontiers in Pharmacology
January 6, 2023
Cited by 7


Related Papers